Treatment of visceral leishmaniasis in south-eastern Nepal: Decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 97, Issue 3, 2003, Pages 350-354

  Rijal, S ^a   Chappuis, Francois ^b   Singh, R ^a   Bovier, P A ^b   Acharya, P ^a   Karki, B M S ^a   Das, M L ^a   Desjeux, P ^c   Loutan, L ^b   Koirala, S ^a  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Chemotherapy; Drug resistance; Leishmania donovani; Nepal; Sodium stibogluconate; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; STIBOGLUCONATE SODIUM;

ADOLESCENT; ADULT; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HUMAN; LEISHMANIA DONOVANI; MAJOR CLINICAL STUDY; MALE; NEPAL; OUTCOMES RESEARCH; POPULATION DISTRIBUTION; POPULATION RESEARCH; PROSPECTIVE STUDY; SCHOOL CHILD; SEPTIC SHOCK; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADULT; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; ENDEMIC DISEASES; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; NEPAL; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

EID: 4444244846     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(03)90167-2     Document Type: Article

References (27)

1. Bern C. Joshi A.B. Jha S.N. Das M.L. Hightower A. Thakur G.D. Bista M.B. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective American Journal of Tropical Medicine and Hygiene 63 2000 184-188
2. Boelaert M. Criel B. Leeuwenburg J. Van Damme W. Le Ray D. Van der Stuyft P. Visceral leishmaniasis control: A public health perspective Transactions of the Royal Society of Tropical Medicine and Hygiene 94 2000 465-471
3. Bryceson A.D.M. Chulay J.D. Ho M. Mugambii M. Were J.B. Muigai R. Chunge C. Gachihi G. Meme J. Anabwani G. Bhatt S.M. Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies Transactions of the Royal Society of Tropical Medicine and Hygiene 79 1985 700-704
4. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance Tropical Medicine and International Health 6 2001 928-934
5. Chunge C.N. Owate J. Pamba H.O. Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate Transactions of the Royal Society of Tropical Medicine and Hygiene 84 1990 221-225
6. Croft S.L. Monitoring drug resistance in leishmaniasis Tropical Medicine and International Health 6 2001 899-905
7. Desjeux P. Leishmaniasis. Public health aspects and control Clinical Dermatology 14 1996 417-423
8. Desjeux P. The increase in risk factors for leishmaniasis worldwide Transactions of the Royal Society of Tropical Medicine and Hygiene 95 2001 239-243
9. Furber A.S. Newell J.N. Lubben M.M. A systematic review of current knowledge of HIV epidemiology and of sexual behaviour in Nepal Tropical Medicine and International Health 7 2002 140-148
10. Jha T.K. Singh N.K.P. Jha S. Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N. Bihar, India Journal of the Association of Physicians of India 40 1992 868 [Abstract]
11. Jha T.K. Sundar S. Thakur C.P. Bachmann P. Karbwang J. Fischer C. Voss A. Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis New England Journal of Medicine 341 1999 1795-1800
12. Karki P. Koirala S. Parija S.C. Handsak S.G. Das M.L. A thirty day course of sodium stibogluconate for treatment of kala-azar in Nepal Southeast Asian Journal of Tropical Medicine and Public Health 29 1998 154-158
13. Lira R. Sundar S. Makharia A. Kenney R. Gam A. Saraiva E. Sacks D. Evidence that the high incidence of treatment failure in kala-azar is due to the emergence of antimony resistant strains of Leishmania donovani Journal of Infectious Diseases 180 1999 564-567
14. Lopez-Velez R. Perez-Molina J.A. Guerrero A. Baquero F. Villarrubia J. Escribano L. Bellas C. Perez-Corral F. Alvar J. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain American Journal of Tropical Medicine and Hygiene 58 1998 436-443
15. Ministry of Health Annual Report. Kalaazar Control 1999/2000 119-124 His Majesty's Government of Nepal, Ministry of Health, Directorate of Health Services, Epidemiology and Disease Control Kathmandu Nepal
16. Josten F. Van Vugt M. Price R. Luxenburger C. Thway K.L. Brockman A. McGready R. Ter Kuile F. Looareesuwan S. White N. Effects of artesunatemefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study Lancet 356 2000 297-302
17. Saxena N.B. Aggarwal V. Dhillon G.P. Sharma R.S. Rao J.S. Visceral leishmaniasis control in India through primary health care system - A successful experiment of district level planning Journal of Communicable Disease 28 1996 122-128
18. Seaman J. Pryce D. Sondorp H.E. Moody A. Bryceson A.D.M. Davidson R. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone Journal of Infectious Diseases 168 1993 715-720
19. Sundar S. Drug resistance in Indian visceral leishmaniasis Tropical Medicine and International Health 6 2001 849-854
20. Sundar S. Thakur B.B. Tandon A.K. Agrawal N.R. Mishra C.P. Mahapatra T.M. Singh V.P. Clinico-epidemiological study of drug resistance in Indian kala-azar British Medical Journal 308 1994 307
21. Sundar S. Rosenkaimer F. Lesser M.L. Murray H.W. Immunochemotherapy for a systematic intracellular infection: Accelerated response using interferon-γ in visceral leishmaniasis Journal of Infectious Diseases 171 1995 992-996
22. Sundar S. More D.K. Singh M.K. Singh V.P. Sharma S. Makharia A. Kumar P.C.K. Murray H. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic Clinical Infectious Diseases 31 2000a 1104-1107
23. Sundar S. Makharia A. More D.K. Agrawal G. Voss A. Fischer C. Bachmann P. Murray H. Short course oral miltefosine treatment for visceral leishmaniasis Clinical Infectious Diseases 31 2000b 1110-1112
24. Thakur C.P. Kanyok T.P. Pandey A.K. Sinha G.P. Zaniewski A.E. Houlihan H.H. Olliaro P. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis Transactions of the Royal Society of Tropical Medicine and Hygiene 94 2000 429-431
25. Veeken H. Ritmeijer K. Seaman J. Davidson R.A. Randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan Tropical Medicine and International Health 5 2000 312-317
26. WHO Control of the Leishmaniases. Report of a WHO expert committee Technical Report Series, No. 793 1990 World Health Organization Geneva
27. WHO Manual on Visceral Leishmaniasis Control 1996 World Health Orgnization Geneva WHO/LEISH/96.40